신경병증성 통증 임상시험 현황 : 동향과 분석(2026년판)

Neuropathic pain is a chronic condition resulting from damage or dysfunction of the peripheral or central somatosensory nervous system. Common causes include diabetic peripheral neuropathy, postherpetic neuralgia, chemotherapy-induced peripheral neuropathy, spinal cord injury, multiple sclerosis, stroke, traumatic nerve injury, and other neurological disorders. Existing therapies, including gabapentinoids, antidepressants, and topical analgesics, frequently provide incomplete pain relief, creating substantial opportunities for novel therapeutic approaches. The current clinical pipeline increasingly targets specific biological mechanisms responsible for chronic neuropathic pain rather than generalized analgesia.

Market Drivers

Rising Burden of Neuropathic Pain

The increasing prevalence of diabetes, cancer survivorship, neurological disorders, and aging populations continues to expand the number of patients living with chronic neuropathic pain, supporting sustained investment in clinical development.

Unmet Need for More Effective Therapies

Current standard treatments often provide limited efficacy and may produce dose-limiting adverse events. This unmet need is encouraging pharmaceutical companies to pursue innovative non-opioid therapies with improved efficacy and safety profiles.

Expansion of Precision Medicine

Developers increasingly utilize biomarkers, sensory phenotyping, genetic profiling, and mechanism-based patient stratification to improve clinical trial success rates and personalize treatment strategies.

Advances in Translational Research

Improved understanding of sodium channel biology, neuroimmune signaling, inflammatory pathways, ion channel modulation, and central sensitization is supporting the identification of novel therapeutic targets and accelerating early-stage clinical development.

Market Restraints

High Placebo Response

Neuropathic pain clinical trials frequently experience substantial placebo responses, making demonstration of statistically significant efficacy challenging and increasing development risk.

Disease Heterogeneity

Neuropathic pain encompasses multiple underlying diseases and biological mechanisms, complicating patient selection, endpoint selection, and interpretation of clinical outcomes.

Complex Clinical Trial Design

Long-duration studies, subjective pain assessments, extensive eligibility criteria, and heterogeneous patient populations continue increasing clinical development complexity and costs.

Clinical Development and Technology Insights

The global neuropathic pain clinical trials landscape can be segmented by development phase, mechanism of action, therapeutic modality, indication, route of administration, sponsor type, and geography.

By development phase, the pipeline includes preclinical, Phase I, Phase II, Phase III, and regulatory review programs. Most investigational programs remain concentrated in early-stage development as sponsors continue validating novel biological targets before progressing into pivotal studies. Phase II programs currently represent the most active stage of clinical development.

By mechanism of action, investigational therapies target selective sodium channel inhibitors, neuroimmune modulators, NMDA receptor antagonists, TRPV1 modulators, monoclonal antibodies, kinase inhibitors, ion channel modulators, and other novel biological pathways. Increasing biological diversity is strengthening the long-term innovation pipeline.

By therapeutic modality, the pipeline includes small molecules, biologics, monoclonal antibodies, RNA therapeutics, gene therapies, regenerative medicine approaches, and combination therapies. Small molecules continue to dominate development because of oral administration, established regulatory pathways, and scalable manufacturing, while advanced biologics and gene therapies represent emerging areas of innovation.

By indication, clinical development addresses diabetic peripheral neuropathy, postherpetic neuralgia, chemotherapy-induced peripheral neuropathy, trigeminal neuralgia, spinal cord injury pain, central neuropathic pain, multiple sclerosis-associated pain, and other neuropathic pain disorders. Diabetic peripheral neuropathy remains the largest commercial opportunity because of its high global prevalence.

Clinical Trial Trends

The neuropathic pain clinical development landscape continues evolving through scientific innovation.

Key trends include:

• Increasing investment in non-opioid therapies.
• Expansion of selective sodium channel inhibitor research.
• Greater use of biomarker-guided patient selection.
• Integration of artificial intelligence into clinical trial design.
• Growth of precision medicine approaches.
• Development of advanced biologics and gene therapies.
• Increasing collaboration between pharmaceutical companies, biotechnology firms, and academic research institutions.

Regional Insights

North America remains the leading region for neuropathic pain clinical development because of advanced clinical research infrastructure, strong regulatory support, high disease awareness, and substantial pharmaceutical investment. The United States hosts a large proportion of global interventional studies.

Europe continues to maintain a strong position through coordinated neurological research networks, standardized treatment guidelines, and collaborative multinational clinical trials. Academic-industry partnerships continue supporting innovative drug development.

Asia-Pacific is emerging as a high-growth region owing to expanding healthcare infrastructure, increasing diabetes prevalence, growing pharmaceutical research capabilities, and improved access to neurological care. China, Japan, South Korea, Australia, and India are becoming increasingly important locations for multinational clinical studies.

Latin America and the Middle East & Africa continue strengthening participation in global clinical research through expanding healthcare infrastructure, improving diagnosis, and increasing investment in neurological disease research.

Competitive Landscape

The neuropathic pain clinical trials landscape includes global pharmaceutical companies, biotechnology firms, academic medical centers, specialty pain research organizations, and contract research organizations.

Organizations continue investing in selective sodium channel inhibitors, neuroimmune modulators, ion channel therapies, monoclonal antibodies, RNA therapeutics, and regenerative medicine platforms. Strategic collaborations, licensing agreements, and translational research partnerships continue accelerating innovation and clinical development.

Future Outlook

The future of neuropathic pain clinical development will increasingly emphasize precision medicine, mechanism-specific therapies, biomarker-guided patient selection, and personalized treatment strategies. Continued advances in neuroscience, artificial intelligence, translational biomarkers, and molecular target identification are expected to improve clinical trial success rates and accelerate commercialization of innovative non-opioid therapies through 2035.

Conclusion

The Global Neuropathic Pain Clinical Trials Analysis demonstrates a rapidly evolving development landscape supported by increasing disease prevalence, significant unmet clinical need, and expanding scientific understanding of pain biology. Although placebo response, disease heterogeneity, and complex trial design remain important challenges, continued advances in mechanism-based therapeutics, precision medicine, and translational neuroscience are expected to create substantial opportunities for pharmaceutical companies, biotechnology firms, researchers, healthcare providers, and investors.

Key Benefits of this Report

• Comprehensive assessment of the global neuropathic pain clinical development landscape.
• Detailed evaluation of investigational therapies across all stages of development.
• Analysis of mechanisms of action, clinical innovation, and emerging therapeutic strategies.
• Competitive intelligence covering pipeline progress, strategic collaborations, and regulatory developments.
• Valuable resource for pharmaceutical companies, biotechnology firms, researchers, healthcare providers, consultants, investors, and policymakers.

What Businesses Use Our Reports For

Pipeline benchmarking, clinical development planning, competitive intelligence, licensing evaluation, partnership identification, investment analysis, commercialization strategy, portfolio optimization, regulatory planning, and long-term strategic decision-making.

Report Coverage

• Historical data from 2021 to 2024, Base Year 2025, and Forecast Period 2026 to 2035
• Comprehensive analysis of the global neuropathic pain clinical trials landscape by development phase, mechanism of action, therapeutic modality, indication, route of administration, sponsor type, and geography
• Evaluation of clinical trial activity, investigational therapies, pipeline maturity, regulatory developments, commercialization opportunities, and innovation trends
• Assessment of strategic collaborations, precision medicine, biomarker-guided development, artificial intelligence integration, and future clinical research opportunities
• Analysis of selective sodium channel inhibitors, neuroimmune modulators, NMDA receptor antagonists, TRPV1 modulators, monoclonal antibodies, kinase inhibitors, small molecules, biologics, RNA therapeutics, gene therapies, regenerative medicine platforms, and emerging neuropathic pain therapies through 2035.

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Report Scope and Objectives
• 1.2 Research Methodology Overview
• 1.3 Global Neuropathic Pain Clinical Development Snapshot
• 1.4 Key Pipeline Highlights
  • 1.4.1 Total Active Clinical Assets
  • 1.4.2 Phase Distribution
  • 1.4.3 Leading Sponsors
  • 1.4.4 Emerging Therapeutic Trends
• 1.5 Key Strategic Insights
• 1.6 Investment Highlights
• 1.7 Commercial Outlook

2. Global Neuropathic Pain Pipeline Overview

• 2.1 Disease Definition and Clinical Scope
• 2.2 Current Treatment Landscape
• 2.3 Unmet Clinical Needs
• 2.4 Evolution of the Neuropathic Pain Drug Pipeline
• 2.5 Pipeline Maturity Assessment
• 2.6 Pipeline Distribution by Development Phase
  • 2.6.1 Preclinical Assets
  • 2.6.2 Phase I Assets
  • 2.6.3 Phase II Assets
  • 2.6.4 Phase III Assets
  • 2.6.5 Filed/Under Regulatory Review
• 2.7 Historical Pipeline Progression Trends
• 2.8 Clinical Development Success Trends
• 2.9 Active versus Inactive Programs
• 2.10 Discontinued and Suspended Development Programs
• 2.11 Asset Origin Analysis
  • 2.11.1 Internal Discovery Programs
  • 2.11.2 In-Licensed Programs
  • 2.11.3 Co-developed Assets
  • 2.11.4 Academic-Origin Programs

3. Disease and Unmet Need Analysis

• 3.1 Disease Burden
• 3.2 Epidemiology Overview
• 3.3 Disease Classification
• 3.4 Major Etiologies
• 3.5 Current Standard of Care
• 3.6 Limitations of Existing Therapies
• 3.7 Safety Challenges
• 3.8 Treatment Gaps
• 3.9 Patient Journey Assessment
• 3.10 Future Therapeutic Requirements

4. Mechanism and Modality Landscape

• 4.1 Mechanism of Action Landscape
• 4.2 Mechanism-Based Clustering
• 4.3 Novel versus Established Mechanisms
• 4.4 First-in-Class versus Best-in-Class Innovation
• 4.5 Mechanism Diversification Trends
• 4.6 Modality Landscape
  • 4.6.1 Small Molecules
  • 4.6.2 Biologics
  • 4.6.3 Cell Therapies
  • 4.6.4 Gene Therapies
  • 4.6.5 RNA-Based Therapeutics
  • 4.6.6 Combination Therapies
• 4.7 Route of Administration Analysis
• 4.8 Target Validation Landscape
• 4.9 Emerging Scientific Innovations
• 4.10 Biomarker Development Trends

5. Clinical Development Intelligence

• 5.1 Clinical Trial Landscape Overview
• 5.2 Trial Volume Trends
• 5.3 Trial Initiation Trends
• 5.4 Trial Completion Trends
• 5.5 Trial Design Benchmarking
  • 5.5.1 Randomization Strategies
  • 5.5.2 Blinding Approaches
  • 5.5.3 Comparator Selection
  • 5.5.4 Adaptive Trial Designs
• 5.6 Sample Size Benchmarking
• 5.7 Primary Endpoint Analysis
• 5.8 Secondary Endpoint Analysis
• 5.9 Clinical Outcome Measures
• 5.10 Trial Duration Benchmarking
• 5.11 Patient Recruitment Analysis
• 5.12 Enrollment Timelines
• 5.13 Geographic Distribution of Clinical Trials
• 5.14 Sponsor Type Analysis
  • 5.14.1 Industry Sponsors
  • 5.14.2 Academic Sponsors
  • 5.14.3 Collaborative Studies
• 5.15 Clinical Success Rates
• 5.16 Failure Analysis
• 5.17 Recruitment Challenges
• 5.18 Patient Dropout Trends
• 5.19 Safety Monitoring Trends
• 5.20 Regulatory Endpoint Alignment

6. Pipeline Segmentation and Asset Intelligence

• 6.1 Pipeline Segmentation by Development Phase
  • 6.1.1 Preclinical Asset Intelligence
    • 6.1.1.1 Asset Profiles (Molecule, Developer, Mechanism, Indication)
    • 6.1.1.2 Innovation Assessment
    • 6.1.1.3 Development Prioritization
  • 6.1.2 Phase I Asset Intelligence
    • 6.1.2.1 Molecule Profiles
    • 6.1.2.2 Developer Profiles
    • 6.1.2.3 Mechanism of Action
    • 6.1.2.4 Clinical Development Status
    • 6.1.2.5 Early Clinical Findings
  • 6.1.3 Phase II Asset Intelligence
    • 6.1.3.1 Molecule Profiles
    • 6.1.3.2 Clinical Trial Status
    • 6.1.3.3 Mechanism Assessment
    • 6.1.3.4 Competitive Positioning
  • 6.1.4 Phase III Asset Intelligence
    • 6.1.4.1 Molecule Profiles
    • 6.1.4.2 Pivotal Trial Assessment
    • 6.1.4.3 Regulatory Readiness
    • 6.1.4.4 Commercial Readiness
  • 6.1.5 Filed and Under Regulatory Review Assets
    • 6.1.5.1 Regulatory Status
    • 6.1.5.2 Submission Milestones
    • 6.1.5.3 Expected Decision Timelines
• 6.2 Pipeline Segmentation by Mechanism of Action
• 6.3 Pipeline Segmentation by Therapeutic Modality
• 6.4 Pipeline Segmentation by Route of Administration
• 6.5 Pipeline Segmentation by Target Biology
• 6.6 Pipeline Segmentation by Sponsor Type
• 6.7 Pipeline Segmentation by Indication
• 6.8 Developer Portfolio Benchmarking

7. Probability of Success and Risk Analysis

• 7.1 Clinical Development Risk Framework
• 7.2 Phase Transition Probability Analysis
  • 7.2.1 Preclinical to Phase I
  • 7.2.2 Phase I to Phase II
  • 7.2.3 Phase II to Phase III
  • 7.2.4 Phase III to Regulatory Submission
  • 7.2.5 Regulatory Submission to Approval
• 7.3 Historical Attrition Analysis
• 7.4 Risk-Adjusted Pipeline Assessment
• 7.5 Asset-Level Probability Modeling
• 7.6 Mechanism-Based Risk Assessment
• 7.7 Sponsor Execution Risk
• 7.8 Clinical Trial Execution Risk
• 7.9 Regulatory Risk Assessment
• 7.10 Commercial Risk Assessment
• 7.11 Probability-Weighted Revenue Potential
• 7.12 Portfolio Value Assessment

8. Launch Timeline and Commercial Potential

• 8.1 Expected Approval Timeline
• 8.2 Launch Sequence Forecast
• 8.3 Commercial Readiness Assessment
• 8.4 Peak Sales Potential
• 8.5 Market Entry Timing
• 8.6 Competitive Launch Window Analysis
• 8.7 Market Access Considerations
• 8.8 Reimbursement Outlook
• 8.9 Pricing Considerations
• 8.10 Lifecycle Management Strategies

9. Competitive Pipeline Landscape

• 9.1 Competitive Environment Overview
• 9.2 Company-Wise Pipeline Strength
• 9.3 Sponsor Ranking by Clinical Assets
• 9.4 Pipeline Concentration Analysis
• 9.5 Innovation Leadership Assessment
• 9.6 Emerging Biotechnology Companies
• 9.7 Large Pharmaceutical Company Positioning
• 9.8 Leader versus Challenger Analysis
• 9.9 Competitive Benchmarking by Mechanism
• 9.10 Competitive Benchmarking by Development Phase
• 9.11 White Space Opportunity Analysis
• 9.12 Strategic Competitive Outlook

10. Geographic Analysis

• 10.1 North America
  • 10.1.1 Clinical Trial Activity
  • 10.1.2 Regulatory Environment
  • 10.1.3 Innovation Ecosystem
• 10.2 Europe
  • 10.2.1 Clinical Trial Activity
  • 10.2.2 Regulatory Environment
  • 10.2.3 Innovation Ecosystem
• 10.3 Asia-Pacific
  • 10.3.1 Clinical Trial Activity
  • 10.3.2 Regulatory Environment
  • 10.3.3 Innovation Ecosystem
• 10.4 Latin America
  • 10.4.1 Clinical Trial Activity
  • 10.4.2 Regulatory Environment
  • 10.4.3 Innovation Ecosystem
• 10.5 Middle East & Africa
  • 10.5.1 Clinical Trial Activity
  • 10.5.2 Regulatory Environment
  • 10.5.3 Innovation Ecosystem

11. Key Countries Analysis

• 11.1 United States
  • 11.1.1 Clinical Trial Activity
  • 11.1.2 Regulatory Timelines
  • 11.1.3 Major Sponsors
• 11.2 Canada
  • 11.2.1 Clinical Trial Activity
  • 11.2.2 Regulatory Timelines
  • 11.2.3 Major Sponsors
• 11.3 Germany
  • 11.3.1 Clinical Trial Activity
  • 11.3.2 Regulatory Timelines
  • 11.3.3 Major Sponsors
• 11.4 United Kingdom
  • 11.4.1 Clinical Trial Activity
  • 11.4.2 Regulatory Timelines
  • 11.4.3 Major Sponsors
• 11.5 France
  • 11.5.1 Clinical Trial Activity
  • 11.5.2 Regulatory Timelines
  • 11.5.3 Major Sponsors
• 11.6 Italy
  • 11.6.1 Clinical Trial Activity
  • 11.6.2 Regulatory Timelines
  • 11.6.3 Major Sponsors
• 11.7 Spain
  • 11.7.1 Clinical Trial Activity
  • 11.7.2 Regulatory Timelines
  • 11.7.3 Major Sponsors
• 11.8 China
  • 11.8.1 Clinical Trial Activity
  • 11.8.2 Regulatory Timelines
  • 11.8.3 Major Sponsors
• 11.9 Japan
  • 11.9.1 Clinical Trial Activity
  • 11.9.2 Regulatory Timelines
  • 11.9.3 Major Sponsors
• 11.10 India
  • 11.10.1 Clinical Trial Activity
  • 11.10.2 Regulatory Timelines
  • 11.10.3 Major Sponsors
• 11.11 South Korea
  • 11.11.1 Clinical Trial Activity
  • 11.11.2 Regulatory Timelines
  • 11.11.3 Major Sponsors
• 11.12 Australia
  • 11.12.1 Clinical Trial Activity
  • 11.12.2 Regulatory Timelines
  • 11.12.3 Major Sponsors
• 11.13 Brazil
  • 11.13.1 Clinical Trial Activity
  • 11.13.2 Regulatory Timelines
  • 11.13.3 Major Sponsors
• 11.14 Mexico
  • 11.14.1 Clinical Trial Activity
  • 11.14.2 Regulatory Timelines
  • 11.14.3 Major Sponsors
• 11.15 Saudi Arabia
  • 11.15.1 Clinical Trial Activity
  • 11.15.2 Regulatory Timelines
  • 11.15.3 Major Sponsors
• 11.16 South Africa
  • 11.16.1 Clinical Trial Activity
  • 11.16.2 Regulatory Timelines
  • 11.16.3 Major Sponsors

12. Deals and Investment Landscape

• 12.1 Licensing Agreements
• 12.2 Co-development Partnerships
• 12.3 Research Collaborations
• 12.4 Mergers and Acquisitions
• 12.5 Joint Ventures
• 12.6 Venture Capital Investments
• 12.7 Private Equity Investments
• 12.8 Public Financing Activities
• 12.9 Government and Non-Profit Funding
• 12.10 Strategic Alliance Trends
• 12.11 Deal Value Analysis
• 12.12 Impact of Partnerships on Pipeline Development

13. Future Outlook and Strategic Insights

• 13.1 Emerging Scientific Directions
• 13.2 Next-Generation Therapeutic Platforms
• 13.3 Future Mechanism Innovation
• 13.4 Clinical Development Outlook
• 13.5 Regulatory Outlook
• 13.6 Commercial Opportunity Assessment
• 13.7 Competitive Evolution
• 13.8 Key Strategic Opportunities
• 13.9 Key Risks and Challenges
• 13.10 Five-Year Pipeline Outlook
• 13.11 Strategic Recommendations for Developers
• 13.12 Strategic Recommendations for Investors

14. Methodology and Data Framework

• 14.1 Research Methodology
• 14.2 Data Collection Framework
• 14.3 Inclusion and Exclusion Criteria
• 14.4 Clinical Trial Registry Sources
  • 14.4.1 ClinicalTrials.gov
  • 14.4.2 EU Clinical Trials Register
  • 14.4.3 Company Pipeline Disclosures
  • 14.4.4 Regulatory Agency Filings
• 14.5 Asset Validation Methodology
• 14.6 Pipeline Classification Framework
• 14.7 Mechanism Classification Methodology
• 14.8 Clinical Phase Assignment Criteria
• 14.9 Probability Modeling Methodology
• 14.10 Commercial Forecasting Methodology
• 14.11 Limitations and Assumptions
• 14.12 Glossary of Terms
• 14.13 Abbreviations
• 14.14 References and Data Sources